Custom mRNA Synthesis

 
With the development of in vitro transcription (IVT) methods, messenger ribonucleotides (mRNA) synthesis has become an emerging class of gene therapy. Serving as the molecular bridge between DNA and proteins, mRNAs and their in vitro transcription technology enable the concept of nucleic acid-encoded proteins for research and therapeutic purposes. The transient nature of mRNA activity also offers an alternative approach to gene editing and gene therapy for delivering genetic information into cells.

To support mRNA research and therapeutic applications, Azenta offers custom mRNA synthesis and circular RNA with industry-leading project completion time, a wide range of deliverables, and best-in-class quality.

Applications of Synthetic mRNA

Therapeutic Development: Treat diseases of protein expression and cellular function without gene editing
Cancer Research: Express tumor antigens or chimeric antigen receptors (CARs) to investigate cancer treatment and response.
CRISPR/Gene Editing: Create targeting mRNA sequences for delivery of CRISPR/Cas9 and other gene editing platforms.
Antibody Development: Translate antibodies in vivo from encoded mRNA instead of from monoclonal production.

Tech Note

Streamlined mRNA Production via Integrated Gene Synthesis and In Vitro Transcription

How do you synthesize mRNA?

Synthetic mRNA comes from a template nucleotide sequence of DNA. The process starts with codon optimization of this sequence for optimal transcription. The gene is synthesized, cloned into a vector, and verified by Sanger sequencing. The plasmid DNA is then amplified, target mRNA sequence linearized, and used as a template for in vitro transcription.

mRNA TranScription Service

 
Clinical-Icon
1. Construct Design


Codon Optimization:

Maximize protein expression and experimental performance with Azenta's propriety codon optimization tool

Clinical-Icon
2. DNA Synthesis

 

Oligo and Gene Synthesis: 99.9% reliability in project delivery rate from a team with over 20 years of gene synthesis experience

Antibody-Icon
3. Cloning and Plasmid Prep


Template Plasmid: 
Performed by our experienced molecular biologists to quickly generate plasmid DNA for IVT based on desired mRNA yield

Antibody-Icon
4. In Vitro Transcription


Scalable Transcription:
   
Mini- to giga-scale quantities of mRNA available to grow with your research program

Antibody-Icon
5. mRNA Purification and QC


High-Quality Ribonucleotides: 
RNA product generated from 100% Sanger sequence-verified template with size visualization and certificate of analysis (CoA)

Featured Application: mRNA Therapeutic Development

 

 

The circularization of coding RNAs into circRNAs has generated considerable interest as an approach to extend the duration of protein translation, thanks to their covalently closed structures and increased stability inside the cells. In the context of RNA-based therapeutics development, this has the potential to unveil better targets or gene delivery vectors with high pharmaceutical stability and biostability relative to current standard-of-care linear mRNA. Azenta has developed a proprietary and first-in-market workflow to produce high-quality circular RNA. Based on a group I intron self-splicing system, our process leads to improved circularization efficiency for high-yield circRNA products with favorable characteristics for therapeutic development.

FragmentGENE

Azenta Features and Benefits

Rapid Project Completion – Gene synthesis to mRNA IVT in as fast as 2 weeks to meet your project deadlines
High Quality mRNA - Stringent quality control of IVT template with guaranteed 100% Sanger sequencing accuracy
Ph.D.–Level Customer Support - Our dedicated project management team provides reliable consultation and support for your project from start to finish
Effortless Project Management – Work with a single research partner for everything from construct design to delivery of purified mRNA
Flexible mRNA Delivery – Suit the needs of your project with a wide range of mRNA types, sequence lengths, and yield of final product
Circular RNA – Proprietary first-in-market commercial workflow to produce high-quality circular RNA (circRNA) for superior pharmaceutical biostability

mRNA Synthesis Deliverables

 

mRNA products are provided as a dry powder, fully lyophilized and shipped at room temperature. Below is a summary of what to expect from your custom mRNA synthesis order.

 

mRNA Synthetic Motifs Purified Synthetic Yield Synthetic Length Estimated Completion Time Quality Control
ncRNA: Non-coding RNA 40 ug – 2000 ug < 2000 bp In as few as 2 weeks - 100% sequence accuracy from Sanger sequencing of template
- Certificate of analysis (CoA)
- Gel electrophoresis size visualization
- Agilent 2100 Bioanalyzer verification (optional)2
Cap0 mRNA: m7Gppp-capped mRNA with polyA tail 2001-4000 bp In as few as 4 weeks
Cap1 mRNA: m7GpppNm-capped mRNA with polyA tail 4001-6000 bp In as few as 5 weeks
Pseudouridine modification (optional)1 > 6001 bp Custom

 

Need mRNA fast for your pilot study? Below is a summary of what to expect from your off-the-shelf GFP mRNA order.

 

coGFP3 control RNAs Scale Estimated Completion Time
Linear with 5’ cap 1 and a ~100A tail 100 ug As fast as 1 week
Circular RNA 20 ug In as few as 2 weeks

 

1. Pseudouridine is a common RNA modification to replace uridine in IVT mRNA. It has been demonstrated to enhance RNA stability and decrease anti-RNA immune response.

2. Agilent 2100 Bioanalyzer utilizes LabChip technology to automate the measurement of both the concentration and the integrity/purity of mRNA samples.

3. Green fluorescent protein (GFP) 2 from Pontellina plumata, also known as ppluGFP2 (Shagin et al., 2004).

If you have custom requests or require any pre-project consultation, please contact our expert project management team.

Technical Resources

Tech Note | High-Fidelity Production of In Vitro Transcription Plasmids with Long Poly(A) Sequences

Poly(A) tail sequences can impact the integrity of your mRNA plasmids for in vitro transcription. While longer poly(A) tails have been shown to increase their stability, tails greater than 100 bases are susceptible to truncations. Learn how the proprietary mRNA plasmid preparation protocol from Azenta can help you generate higher yields and preserve poly(A) tails of greater lengths compared to standard protocols for high-fidelity templates in our tech note.

Tech Note | mRNA Production via Integrated Gene Synthesis and In Vitro Transcription

In vitro transcription (IVT) is a powerful technique to generate messenger RNA (mRNA) for a wide array of research and therapeutic applications. Transfection of mRNA enables very high protein expression, comparable to viral systems, with rapid onset. Read our tech note to learn how IVT, coupled with gene synthesis, can be used to synthesize mRNA of virtually any sequence quickly and efficiently.

Poster | Optimizing mRNA Vaccines and Virus-Mediated CAR T-Cell Therapy for Immuno-Oncology

Lentiviral vectors have proven effective at delivery of genetic material or gene editing technology for ex vivo processing, but the benefits and promise of Adeno-associated virus (AAV) and mRNA tools for in vivo immunotherapy have garnered recent interest. In this poster, we present streamlined approaches for lentiviral, AAV, and mRNA production that improves data quality through innovative synthesis and sequencing methodologies as compared to current standards

HOW TO ORDER


Email | Phone: +49 (0)341 520 122-41